Pancreatic lipase Inhibitors
1 drugsAbout Pancreatic lipase
Pancreatic lipase is a digestive enzyme that breaks down dietary fats into absorbable molecules. Inhibiting this enzyme reduces fat absorption in the intestines, impacting overall metabolism.
Pancreatic lipase is a therapeutic target for managing metabolic disorders like obesity by reducing fat absorption. Currently, there is no genetic evidence directly linking pancreatic lipase to specific diseases.
Pancreatic lipase is targeted by one FDA-approved drug, Xenical (orlistat), a small molecule. Cheplapharm is the sole company with an approved drug targeting this enzyme in the metabolic therapeutic area.
Top Pancreatic lipase Drugs
Cheplapharm is the only company with an approved drug targeting pancreatic lipase.
Low competition suggests an opportunity for new entrants, but also indicates potential challenges in market viability.
Pancreatic lipase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Pancreatic lipase, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies and potentially improve efficacy.
Pancreatic lipase Clinical Trials 24 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Pancreatic lipase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 10 | 4 | 2 | 4 | 67% |
| Phase 3 | 3 | 3 | 0 | 0 | 100% |
| Phase 4 | 9 | 6 | 2 | 1 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Pancreatic lipase Drug Approval Timeline (1999 - 1999)
The first and only drug, Xenical, was approved in 1999.
The lack of recent approvals suggests market saturation or challenges in developing improved pancreatic lipase inhibitors.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 20 (6 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Pancreatic lipase. A trial counts if an approved drug acting on Pancreatic lipase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.